Inhibition of alveolar bone loss by matrix metalloproteinase inhibitors in experimental periodontal disease

Journal of Periodontal Research

Volumn 37, Issue 1, 2002, Pages 1-7

  Ramamurthy, Nungavaram S ^a   Xu, Jing Wen ^b   Bird, John ^c   Baxter, Andrew ^c   Bhogal, Ranjev ^c   Wills, Ruth ^c   Watson, Bob ^c   Owen, David ^c   Wolff, Mark ^a   Greenwald, Robert A ^a,b,d  

^a STONY BROOK UNIVERSITY   (United States)

^b LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^c UCB PHARMA   (Belgium)

^d NONE   (United States)

Author keywords

Alveolar bone; Collagenase; Cytokine; Matrix metalloproteinase; Periodontal disease

Indexed keywords

ADAM PROTEIN; CARRIER PROTEIN; CH1766; CH6631; COLLAGENASE; ENDOTOXIN; GELATINASE; HYDROXAMIC ACID; INTERLEUKIN 1; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MATRILYSIN; MATRIX METALLOPROTEINASE; METALLOPROTEINASE; PROTEINASE INHIBITOR; STROMELYSIN; SULFONAMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR-ALPHA CONVERTASE;

ANIMAL; ARTICLE; CEPHALOMETRY; DISEASE MODEL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; ESCHERICHIA COLI; GINGIVA; JAW; MALE; OSTEOLYSIS; PATHOLOGY; PERIODONTITIS; RAT; SCANNING ELECTRON MICROSCOPY; SPRAGUE DAWLEY RAT;

ADAM PROTEINS; ALVEOLAR BONE LOSS; ALVEOLAR PROCESS; ANIMALS; CARRIER PROTEINS; CEPHALOMETRY; COLLAGENASES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTOXINS; ESCHERICHIA COLI; GELATINASES; GINGIVA; HYDROXAMIC ACIDS; INTERLEUKIN-1; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MALE; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 7; MATRIX METALLOPROTEINASES; METALLOENDOPEPTIDASES; MICROSCOPY, ELECTRON, SCANNING; PERIODONTITIS; PROTEASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; SULFONAMIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036482314     PISSN: 00223484     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0765.2002.00342.x     Document Type: Article

References (27)

1. Greenwald RA, Kirkwood K. Adult periodontitis as a model for RA (with emphasis on treatment strategies). J Rheunt 1999,26:1650-1653.
2. Golub LM, Greenwald RA, Ramamurthy NS, McNamara TF, Rifkin BR. Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs Crit Rev Oral Biol Med 1991;2:297-322.
3. Ryan M, Greenwald RA, Golub LM, Potential of tetracyclines to modify cartilage breakdown in osteoarthritis. Curr Opin Rheumatol 1996:8:238-247
4. Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J. Sorsa T. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 1998;12:12-26.
5. Thomas J, Walker C, Bradshaw J. Long-term use of subantimicrobial dose doxycycline does not lead to changes in antimicrobial susceptibility. J Periodontol, 2000;71: 1472-1483.
6. McGeehan GM, Becherer JD, Bast J. Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor. Nature 1994;370.558-561.
7. Montana J, Baxter AD, Owen DA, Watson RJ, Phillipson N. Peptidyl compounds and their therapeutic use as inhibitors of metalloproteases. PCT Int Appl 1996; CODEN PIXXD2 WO 9611209 Al 19960418 (patent).
8. Montana JG, Baxter AD, Owen DA, Watson RJ. Preparation of tetrahydropyran-4-carboxylates as matrix metalloproteinase inhibitors. WO 9940080 Al 19990812 (patent).
9. Knight CG. Willenbrock F, Murphy G. A novel coumarinlabelled peptidc for sensitive continuous assays of the matrix metatloproteinases. FEBS Lett 1992;296:263-266.
10. Ramamurthy NS, Greenwald RA, Schneir M, Golub LM. The effect of alloxan diabetes on prolyl and lysyl hydroxylase activity in uninflamed and inflamed rat gingiva. Arch Oral Biol 1985,30:679-683.
11. Chang KM, Ryan ME, Golub LM, Ramamurthy NS, McNamara TF. Local and systemic factors in periodontal disease increase matrix-degrading enzyme activities in rat gingiva: effect of minocycline therapy. Res Commun Mol Pathol Pharmacol 1996;91 303-310.
12. Ramamurthy NS, Golub LM, Gwinnett AJ, Salo T, Ding Y, Sorsá T. In vivo and in vitro inhibition of matrix metalloproteinases including MMP-13 by several chemically modified tetracyclines (CMTs). In: Davidovitch D, Mah J, eds. Biologic mechamsms of tooth eruption, resorption and replacement by implants. Boston: Harvard Society for the Advancement of Orthodontics, 1998: 271-277.
13. Llavaneras A, Golub LM, Rifkin BR et al. CMT-8/ clodronate combination therapy synergistically inhibits alveolar bone loss in LPS-induced periodontitis. Ann N Y Acad Sci 1999;878.671-674
14. Golub LM, Wolff M, Lee HM et al. Further evidence that tetracyclines inhibit collagenase activity in human crevicular fluid and from other mammalian sources. J Periodont Res 1985;20:12-23.
15. Golub LM, Evans RT. McNamara TF, Lee HM, Ramamurthy NS. A non-antimicrobial tetracycline inhibits gingival matrix metalloproteinases and bone loss in Porphyromonas gingivalis-induced periodontitis in rats. Ann N Y Acad Sci 1994;732:96-111.
16. Ryan ME, Ramamurthy NS, Golub LM. Matrix metallo-proteinases and their inhibition in periodontal treatment. Curr Opin Periodonot 1996;3:85-96.
17. Hausmann E, Nair BC, Dziak R. Bacterial components which result in bone loss. In: Genco RJ, Mergenhagen SE, eds. Host-parasite interactions in periodontal diseases. Washington DC: American Society for Microbiology, 1982:151-159.
18. Gregory SH. Endotoxin stimulated mononuclear phagocytes secrete soluble factors with bone resorbing activity. J Periodont Res 1988;23:7-12.
19. Wahl LM, Wahl SM, Mergenhagen SE, Martin GR. Collagenase production by endotoxin activated macrophages. Proc Natl Acad Sci U S A 1974;71:4955-4958.
20. Meikle MC, Atkinson SJ, Ward RV, Murphy G, Reynolds JJ. Gingival fibroblasts degrade type-1 collagen when stimulated with tumor necrosis factor and interleukin-1. J Periodont Res 1989;24:207-213.
21. Sorsa T. Ingman T, Suomalainen K et al. Cellular source and tetracycline inhibition of gingival crevicular fluid collagenase of patients with labile diabetes mellitus. J Clin Periodontal 1992;19:146-149.
22. Hanemaaijer R, Sorsa T, Konttinen Y et al. Matrix metalloproteinase-8 is expressed in rheumatoid synovial fibroblasts and endothelial cells. J Biol Chem 1997; 272:31504-31509.
23. Ashley RA. Clinical trials of a matrix metalloproteinase inhibitor in human periodontal disease. Ann N Y Acad Sci 1999;878:335-346.
24. Caton J, Ciancio S, Blieden TM et al. Treatment with subantimicrobial dose doxycycline improves the efficacy of scaling and root planing in patients with adult periodontitis. J Periodontol 2000;71:521-532.
25. Karatzas S, Robledo P, Mitchell P, Tohme Z, Trujillo A, Vandyke T. The effect of matrix metalloproteinase inhibitor on the progression of periodontal disease. J Dent Res 2000;79, abstract 1588
26. Golub LM, Lee HM, Greenwald RA et al. A matrix metalloproteinase inhibitor reduces bone-type collagen degradation fragments and bone-type collagenase in gingival crevicular fluid during adult periodontitis. Inflamm Res 1997;46:310-319.
27. Golub LM, Suomalainen K, Sorsa T. Host modulation with tetracyclines and their chemically modified analogues. Curr Opinion Dent 1992;2:80-90.